A cost-utility analysis found that concurrent phacoemulsification and minimally invasive glaucoma surgery using trabecular microbypass stents is cost-effective for treating mild to moderate open-angle glaucoma, compared with cataract surgery alone.
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
A recently developed tool can help ophthalmologists to assess the quality of findings from real-world studies in retinal diseases. This will help them decide which results are most robust and applicable to their practice.
Giving due consideration to preoperative marking and the surgical technique in toric IOL implantation, as well as being diligent about reviewing postoperative results, can improve patient outcomes whilst minimising the chance of errors.
In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.
With minimally invasive surgery procedures becoming increasingly popular in glaucoma management, canaloplasty using an ab-interno surgical technique offers enhanced natural aqueous outflow in open-angle glaucoma.
A recent prospective study analysed the relationship between corneo-scleral geometry and the axial length of the eye to develop preliminary prediction models of the axial length of the eye based on clinical data.